Industrial, Manufacturing & Heavy Industry Market News

Epigenetics market to hit $1,605.7 mn by 2022

The global epigenetics market is projected to reach USD 1,605.7 million by 2022 from USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period. 

- Advertising -

Epigenetics Market research report review 2017-2022 of 230 pages added by reports and reports explores global Epigenetics Market size database, current trends and shares, analysis, techniques, growth, opportunity, application, end user, and region and key company analysis to 2022. Report provides Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO). 

Access sample report@…aspx?name=215227


The global epigenetics market is broadly segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa. North America accounted for the largest share of the global epigenetics market in 2016, while Asia Pacific is projected to register the highest growth rate during the forecast period.

Factors such as increasing R&D spending, favorable government initiatives, and rising focus ofkey market players on enhancing their presence in this region are supporting the growth of the epigenetics market in the Asia Pacific.

- Advertising -

The decreasing sequencing costs and time, increasing research activities, favorable funding scenario for epigenetics research, rising prevalence of cancer are the key factors driving market growth during the forecast period. On the other hand, the high cost of instruments is expected to restrain the growth of this market to a certain extent.

Access report at…aspx?name=215227

*Top 12+ players in the epigenetics market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US) and others.

Correct Target Audience of this Epigenetics Market is:

  • Manufacturers and Vendors of Epigenetic Kits and Instruments
  • Academic and Research Institutes
  • Contract Research Organizations
  • Pharmaceutical and Biotechnology Companies
  • Research and Consulting Firms
  • Venture Capitalists

Access complete report  @

On the basis of application, the epigenetics market is segmented into oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and other applications (includes neurology, gynecology, and infectious diseases).

On the basis of end users, the epigenetics market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment is expected to register the highest CAGR during the forecast period, owing to increasing research in the areas of genomics with a strong focus on personalized medicine.

Fundamental from Table of Content 

7 Epigenetics Market, By Application
7.1 Introduction
7.2 Oncology
7.3 Metabolic Diseases
7.4 Developmental Biology
7.5 Immunology
7.6 Cardiovascular Diseases
7.7 Other Applications 

8 Epigenetics Market, By Technology
8.1 Introduction
8.2 DNA Methylation
8.3 Histone Modification
8.4 Other Technologies 

9 Epigenetics Market, By End User
9.1 Introduction
9.2 Academic and Research Institutes
9.3 Pharmaceutical and Biotechnology Companies
9.4 Contract Research Organizations

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany about: provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..
This email address is being protected from spambots. You need JavaScript enabled to view it.